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The maxillofacial skeleton is highly dynamic and requires a constant equilibrium between
the bone resorption and bone formation. The field of osteoimmunology explores the
interactions between bone metabolism and the immune response, providing a context
to study the complex cellular and molecular networks involved in oro-maxillofacial
osteolytic diseases. In this review, we present a framework for understanding the potential
mechanisms underlying the immuno-pathobiology in etiologically-diverse diseases that
affect the oral and maxillofacial region and share bone destruction as their common
clinical outcome. These otherwise different pathologies share similar inflammatory
pathways mediated by central cellular players, such as macrophages, T and B cells,
that promote the differentiation and activation of osteoclasts, ineffective or insufficient
bone apposition by osteoblasts, and the continuous production of osteoclastogenic
signals by immune and local stromal cells. We also present the potential translational
applications of this knowledge based on the biological mechanisms involved in the
inflammation-induced bone destruction. Such applications can be the development
of immune-based therapies that promote bone healing/regeneration, the identification
of host-derived inflammatory/collagenolytic biomarkers as diagnostics tools, the
assessment of links between oral and systemic diseases; and the characterization of
genetic polymorphisms in immune or bone-related genes that will help diagnosis of
susceptible individuals.
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INTRODUCTION
The maxillofacial skeletal structure has a complex geometry,
adapted to the high mechanical requirements of the
masticatory function. In this complex system, the alveolar bone
accommodates the teeth and periodontal tissues while the basal
bone provides support and insertion of masticatory muscles.
Also, the mandible has two bilateral vertical rami that articulate
with the base of the skull to form the temporomandibular joint
(TMJ). Under physiological conditions, the bone undergoes
continuous remodeling in a dynamic equilibrium of bone
resorption by osteoclasts and bone formation by osteoblasts, at
anatomically discrete sites known as basic multicellular units
(BMUs) (1). Tight control of bone remodeling at the BMUs level
is necessary to conserve structural integrity as the formation
component needs to replace the exact amount removed by
resorption. The strict synchronization of bone resorption and
formation is referred to as coupling, a term that applies to each
BMUs along with the skeleton (2). Bone coupling is controlled
through a complex cellular communication network regulated
by the signaling between osteoblasts, their mesenchymal pre-
osteoblastic precursors, osteocytes, and osteoclasts and their
monocytic precursors (1). Although circulating hormones,
including PTH and 1,25-dihydroxyvitamin-D3, are considered
to be the critical regulators of bone remodeling, it has become
clear that locally generated cytokines are the key modulators of
bone-cells communication and function (2).
The field of osteoimmunology has provided insight into the
mechanics of osteoclast differentiation and activation during
inflammation by immune cells and their soluble products.
This process is fundamentally regulated by a triad of proteins
of the tumor necrosis factor/tumor necrosis factor receptor
family namely the receptor activator of nuclear factor κB ligand
(RANKL), its functional receptor (RANK), and its soluble decoy
receptor osteoprotegerin (OPG). Both soluble and membrane-
bound RANKL can induce osteoclastogenesis through RANK in
osteoclast precursors. Meanwhile, OPG inhibits the interaction
between RANKL and RANK, and arrests osteoclastogenesis
(3, 4). Under homeostatic conditions, RANKL is produced
mainly by osteocytes, which have a higher capacity to support
osteoclastogenesis than osteoblasts and are essentials for bone
remodeling (5, 6). Interestingly, osteoblasts also produce RANKL
which acts as an acceptor for vesicular RANK produced
by mature osteoclasts. The osteoblastic RANKL-RANK cross-
linking triggers RANKL reverse signaling, which promotes bone
formation through the increased expression of early regulators
of osteoblast differentiation (7). Under inflammatory conditions,
however, the sources of RANKL are increased; immune cells such
as particular subtypes of T cells and B cells can also produce
RANKL (8). In addition, the local secretion of pro-inflammatory
cytokines, such as IL-17 can induce the production of RANKL
by osteoblasts and fibroblasts with osteoclastogenic capacity
(9) suggesting a highly complex network of cellular origins of
RANKL activity in tissues induced by inflammation.
In addition to osteoclast differentiation, inflammation impacts
bone formation. Anabolic bone apposition is generally sustained
by the expression of different growth factors such as fibroblast
growth factors (FGFs), platelet-derived growth factors (PDGFs),
insulin-like growth factors (IGFs), tumor growth factor β
(TGF-β), bone morphogenetic proteins (BMPs), and Wnt
proteins, released from the bone matrix or produced locally
by different cell types (10–14). In particular, the Wnt/β-
catenin and Bmp/Runx2 signaling pathways are essential for
bone mass maintenance by regulating the differentiation and
anabolic bone-formation activity of osteoblasts and osteocytes
(15, 16). However, during inflammation, the activation of the
classical (or canonical) NF-κB pathway inhibits the production
of bone matrix proteins by decreasing the Bmp2-stimulated
Runx2 and Wnt-stimulated β-catenin binding to osteocalcin
and bone sialoprotein promoters (12). Inflammation also
induces the production of the Wnt/β-catenin pathway inhibitors
Dickkopf factor-1 (DKK1) and sclerotin (17, 18). The decline
of inflammation restores the osteoblast functions by activating
the canonical Wnt/β-catenin pathway (19), which has been
shown to up-regulate OPG expression and inhibit osteoclast
differentiation (20). Accumulating evidence, therefore, points
to the failure of endogenous inflammation-resolution pathways
as an underlying factor in the initiation and progression of
chronic osteolytic inflammatory diseases and their relationship
with systemic diseases.
In osteolytic inflammatory diseases such as periodontal
disease, apical periodontitis, maxillofacial bone sarcomas
and osteoarthritis of the TMJ, inflammation results in tissue
destruction by the continuous release of osteoclastogenic
mediators that counteract the production of bone-coupling
signals. These otherwise different diseases share similar
inflammatory pathways mediated by central cellular players, such
as macrophages, T and B cells, that promote the differentiation
and activation of osteoclasts, ineffective or insufficient bone
apposition by osteoblasts, and the continuous production of
osteoclastogenic signals by immune and local stromal cells.
In the present review, we focused on the immune pathways
that lead to the clinical signs of bone loss in different oro-
maxillofacial diseases and possible translational applications of
this knowledge.
PERIODONTAL DISEASE
Definition and Pathogenesis of the
Periodontal Disease
Among the osteolytic chronic inflammatory disorders of the
jaws, periodontitis is the most well-defined and studied. The
mechanisms underlying the pathogenesis of periodontitis are
complex as periodontitis is a multifactorial disease that requires
the combination of both a susceptible host and a dysbiotic
polymicrobial community (21). Periodontitis is a significant
public health problem due to its high prevalence, its cause
of tooth loss, and its association with systemic diseases (22).
Host susceptibility to periodontal diseases is the combination
of genetic, epigenetic, behavioral, and environmental factors
that modulate the immune response and the conditions
of maintenance of the microbial community that colonizes
the pathogenic biofilm (23, 24). The periodontitis-associated
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microbial communities not only stimulate but also exploit
inflammation as a way to obtain nutrients for growth and
persistence. The virulence factors of the bacteria can inhibit the
antimicrobial functions and promote the pro-inflammatory and
tissue-destructive properties of the host immune response to
escape annihilation; consequently exacerbating and perpetuating
the disease (21, 25). Thus, the interactions between the host and
the microorganisms in periodontal disease are not only complex
but also evolving.
Cellular and the Molecular Immune Basis
of the Periodontal Disease
The immune response during periodontitis involves different
elements of innate and adaptive immunity. One of the first
responders during the pathogenesis of periodontitis is the
complement system, first recognized in early clinical studies that
associated the disease with the presence of activated complement
fragments in the gingival crevicular fluid (GCF) (26, 27). The use
of animal models helped to clarify the role of complement-related
mechanisms during periodontitis and alveolar bone loss (26, 28).
These studies have highlighted the synergistic cross-talk of the
complement with TLR pathways. For example, the activation
of both C5aR1 and TLR2 by specific agonists resulted in the
induction of significantly higher levels of pro-inflammatory
cytokines in the gingiva (28). Mice lacking C5aR1 are resistant
to bone-destructive diseases such as periodontitis and arthritis
(29, 30), attributed to the critical role of the anaphylatoxin
receptors in initiating neutrophils and macrophages adhesion
and recruitment, necessary for the induction of bone resorption
(31). Also, P. gingivalis targets C5aR to promote its adaptive
fitness by manipulating the activation of TLR2 via the C5a-
C5aR axis, allowing it to escape the IL-12p70-dependent immune
clearance. This C5aR1-dependent evasion mechanism is crucial
for the induction of microbial dysbiosis (29, 32).
Periodontal health is particularly sensitive to neutrophil
functions and dysfunctions. Both hyper- and hypo-
responsiveness of neutrophils have been associated with
dysregulated inflammatory response and bone loss (33).
Rare diseases related to defective extravasation of circulating
neutrophils (LAD-1 deficiency) or neutrophil functionality
(Papillon-Lefèvre syndrome) display a severe and fast-
progressive form of periodontitis (34). If neutrophils cannot
reach the gingiva, there is an overproduction of IL-23, IL-17, and
G-CSF in the periodontium, attributed to macrophages, which
in turn induces further inflammation and osteoclastogenesis
(35). P. gingivalis possesses virulence factors that disrupt the
neutrophil responses. For example, the LPS-induced TLR2
activation and cross-talk with C5aR inhibits the Myd88 but
activates the Mal-PI3K pathway; this abolishes the antimicrobial
response and PI3K-mediated phagocytosis while triggering
the Mal-dependent inflammation (36). P. gingivalis can inhibit
opsonization and phagocytosis, enhance neutrophil recruitment
and respiratory burst, thus incrementing the neutrophil-
associated inflammation and tissue damage (37). Neutrophils
may also possess a hyper-inflammatory phenotype characterized
by the over-expression of reactive oxygen species and pro-
inflammatory cytokines (IL-1β, IL-6, IL-8, and TNF-α), which
along with their other defective functions such as phagocytosis
and chemotaxis, contribute to additional tissue-damage and
comorbidity with other inflammatory diseases (38, 39). In
the context of osteoimmunological regulation of periodontal
diseases, neutrophils display heterotypic adhesion to osteoblast
and modulate their function (40) and possess a regulatory role
during microbial infection by secreting the anti-inflammatory
cytokine IL-10 (41). Neutrophils acquire regulatory functions
by direct cell-to-cell contact with regulatory T (Treg) cells or by
exogenous IL-10 stimuli. The IL-10-producing neutrophils have
been found in the purulent exudate collected from periodontal
pockets in patients with chronic periodontitis; their role in
the resolution of periodontal inflammation still needs to be
investigated (42).
Even thoughmacrophages are in low quantities in periodontal
tissues (43), they participate in the pathogenesis of periodontitis
as central players by initiating or resolving inflammation,
contributing to tissue repair, activating lymphocyte-mediated
adaptive immunity and mediating alveolar bone resorption
and apposition (44). During inflammation, tissue-resident
macrophages are expanded, and circulating monocytes are
recruited to be differentiated into macrophage-like cells (45).
Macrophages are divided into two functionally different subtypes:
M1 classically-activated macrophages, produced in response
to IFN-γ, TNF-α, IL-1β, and IL-6, with pro-inflammatory,
antibacterial and antiviral functions; M2 alternatively-activated
macrophages, produced in response to IL-4 and IL-13, with
anti-inflammatory and tissue-repair/regeneration functions that
expresses high levels of IL-10 (46–48). While these classes are
clearly defined in mice; in humans, macrophages represent
a continuum of highly plastic effector cells, resembling a
spectrum of diverse phenotype states (47). Both M1 and
M2 macrophages are increased in periodontitis compared to
controls, yet the M1/M2 ratio is higher in periodontitis and is
associated with increased expression of M1-related molecules
such as IL-1β, IL-6 and matrix metalloproteinase (MMP)-9
(48, 49). Circulating monocytes/macrophages are affected by
experimental periodontitis and display an M1 phenotype by
overexpressing TNF-α and IL-6 (50). The temporal analysis of
inflammation to healing osteolytic periodontal lesions showed a
shift in themacrophage activation from inflammatory (CD80 and
TNF-α expression) to resolving (CD206 expression) phenotype,
which correlated to bone loss (51).
Lymphocytes are the majority of all CD45+ hematopoietic-
origin cells within the normal gingival mucosa (43) and
play a key role in osteoimmunology. The CD3+ T cell
compartment is the dominant population in both health and
disease, reflecting a 10-fold increase in total inflammatory
cells (43). The analysis of alveolar bone resorption during
P. gingivalis-induced experimental periodontitis in MHC-I or
MHC-II deficient mice showed the destructive role for CD4+
T cells (52); yet effector-memory CD8+ T cells are present
in normal gingival mucosa (43) suggesting a protective role
for CD8+ T cells during periodontitis possibly due their
ability to suppress osteoclastogenesis (53). Upon activation by
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the APCs, CD4+ T cells are polarized into distinct effector
phenotypes depending on the nature of the antigen, co-
stimulatory signals, and the local cytokine milieu (22). These
phenotypes are Th1, Th2, Th9, Th17, Th22, and Treg, each with
a particular transcription factor, often called a master switch,
that modulates the phenotypic differentiation and particular
effector-functions making these phenotypes highly plastic (54).
Each phenotype has different involvement in the pathogenesis
of periodontitis. They can be broadly classified in two axes:
(1) Th1/Th17 pro-inflammatory and osteoclastogenic and (2)
Th2/Treg mechanistically implied in the arrest of the disease
and progression (55). Th9 and Th22, which are relatively new-
subsets, have been scantily characterized in periodontal disease.
Th22 cells were increased in gingival biopsies in periodontitis,
associated with the increased osteoclastic activity, and triggered
upon stimulation with the periodontal pathogen Aggregatibacter
actinomycetemcomitans (56, 57).
Th1 cells produce pro-inflammatory cytokines such as
IFN-γ, IL-12, IL-1β, and TNF-α, under the control of the
transcription factor T-bet (22). The Th1-type of response,
mediated by the production of IFN-γ, is necessary for
both the control of microbial invasion and bone loss. The
induction of periodontitis with A. actinomycetemcomitans in
IFN-γ-deficient mice resulted in a less severe bone loss
but impaired host defense against the microbial challenge,
followed by a disseminated bacterial infection and mice
death (58). P. gingivalis promotes the expression of type-
1 interferons by disrupting innate immunological functions
through degradation of Myd88, resulting in a constitutively
priming of CD4+ T-cells by dendritic cells and leading to
elevated IFN-γ and RANKL expression associated with increased
alveolar bone loss. Blocking type-I IFN signaling prevented
the destructive Th1 immune response and alveolar bone
loss (59).
Th17 cells are the most osteoclastogenic type of T-cells,
directly expressing and inducing RANKL expression on resident
cells through IL-17 production, and necessary to sustain the
host defense against the dysbiotic microbial community. Th17
cells produce IL-17A, IL-17F, and IL-22, under the control
of the master switch RORγ, and the critical participation of
the transcription factor STAT3 (60). In healthy individuals,
Th17 cells naturally accumulate in the gingival mucosa with
age and promote barrier defense. This growth depends on
mechanical stimulation, such as chewing, which induces the
production of IL-6 in epithelial cells, and is independent of
commensal bacteria (61). The expansion of the Th17 cells during
periodontitis, on the other hand, is dependent on microbial
dysbiosis and requires both IL-6 and IL-23 production (62).
These are predominantly resident memory Th17 cells, capable
of quick responses and the primary producers of IL-17. A
recent study in mice confirmed that IL-17 producing Th17
cells rather than γδT cells are involved in bone damage during
periodontitis. IL-17 production is necessary for host defense
against the invasion of oral bacteria (9). Also, a significant
proportion of the IL-17 producing Th17 cells were exFoxp3Th17,
cells that expressed high amounts of membrane-bound RANKL,
suggesting that at some point, these cells might have had
regulatory functions (9). Accordingly, patients with autosomal-
dominant STAT3 deficiency (AD-HIES), are less susceptible to
periodontitis (62).
The Th2 and Treg type of responses are implicated in the
resolution of periodontitis (63). Th2 cells produce IL-4, IL-
5, and IL-13, and mediate humoral immunity and mast cell
activation in allergic reactions (22). Treg cells produce IL-10
and TGF-β and are crucial for the maintenance of immune
homeostasis and tissue repair under the control of the master
switch Foxp3 (64). Tregs inhibit osteoclast differentiation and
their bone resorptive activity through the interaction of CTLA-
4 with CD80/86 on osteoclasts and their precursors (29). Both
Th2 and Treg cells express the chemokine receptor CCR4.
The induction of periodontitis in CCR4−/− mice presented
a significant deficiency of Treg migration, associated with
increased inflammatory alveolar bone loss (63).
B cells are practically not present in normal gingival
mucosa (43), but they dramatically increase as the disease
progresses, making it a distinct feature of the established
periodontal lesion (22). During periodontitis, stromal cells
and immune cells express different cytokines and chemokines
such as IL-4, IL6, IL-5, CXCL13, and APRIL that induce B
cell migration and support their survival in the periodontium
(65, 66). Patients with periodontitis have a significantly higher
percentage of CD19+CD27+CD382− memory B cells and
CD138+HLA-DRlow plasma cells while B1 cells, which have
been previously described as a regulatory type of B cell
(CD20+CD69−CD43+CD27+CD11b+) are decreased (67, 68).
B cells/plasma cells are well-known for their humoral immunity.
However, periodontitis progresses despite the presence of B cells
and the induction of humoral responses against periodontal
bacteria. The B cell-mediated IgG-dominant immune response
might contribute to the pathogenesis of periodontitis (65,
68). Most infiltrating B cells present during periodontitis
produce RANKL, suggesting that they can directly induce
osteoclastogenesis (8). Indeed, the induction of experimental
periodontitis in B cell-deficient mice showed significantly less
bone loss (65). Latest data demonstrated the existence of a
regulatory B cell subtype (Bregs) that can inhibit inflammation
and support Treg differentiation through their production of
IL-10. Bregs cells in humans have been identified as both
CD19+CD24hiCD38hiCD1dhi and CD19+CD24hiCD27+ cells
(69). In mice, the functional IL-10-producing subset of Bregs,
B10, have bone protective roles during periodontitis (70).
Osteoimmunological Processes in the
Periodontal Disease
The periodontium offers a unique environment to understand
the interactions between the immune system and bone since
it combines mucosal and skeletal tissues and the interaction
between the host and the oral microbiota (21). The alveolar
bone is susceptible to different types of mechanical stress and
is continuously remodeled by the coupled action of osteoclasts
and osteoblasts within the bone surface (3, 71). As reviewed
above, the immune response caused by the dysbiotic microbiota
during periodontitis dramatically enhances the production of
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local RANKL by different immune cell types such as Th17
and B cells. However, recent studies with specific cell type-
depleted animals have highlighted the impact of RANKL
production by osteocytes, osteoblasts, and periodontal ligament
cells on osteoclast differentiation and alveolar bone loss (72).
Osteocytes respond to inflammation, specifically to IL-6 and IL-
17, by producing RANKL and increasing their osteoclastogenesis
(73, 74). In a P. gingivalis and Fusobacterium nucleatum-
induced periodontitis model, the genetic depletion of RANKL in
osteocytes decreased the alveolar bone destruction and osteoclast
differentiation (75). Osteocytes react to P. gingivalis LPS by
producing sclerostin, which reduces osteoblastic bone formation
by inhibiting the Wnt/β catenin signaling pathway (76).
Osteoblasts and periodontal ligament cells also respond to IL-
17, producing RANKL, and decreasing OPG production (77).
The osteoblastic inflammatory-mediated RANKL production
depends on the activation of the classical NF-κB pathway. The
inhibition of NF-κB activation in osteoblastic lineage cells inmice
reduces osteoclast numbers and RANKL expression induced
by periodontal infection (72). Specific genetic depletion of
RANKL production in osteoblasts and periodontal ligament cells
during ligature-induced periodontitis reduces the alveolar bone
resorption in an even greater extent that the RANKL depletion
on CD4+ cells (9). Osteocytes, osteoblasts, and periodontal
ligament cells significantly contribute to osteoclastogenesis
during periodontitis by translating inflammatory signals into
RANKL overexpression, often paired with OPG downregulation.
This process results in the disruption of the coupling of bone
resorption and apposition (Figure 1) (77). A recent study further
demonstrated that bone matrix-derived products activate the
NLRP3 inflammasome and stimulate osteoclast differentiation
(78). The intracellular multi-protein complex known as the
inflammasome functions as a molecular platform that triggers
the activation of caspase-1, necessary to proteolytically process
the biologically inactive form of IL-1β and IL-18 into mature
cytokines. This conversion is key since RANKL acts in concert
with TNF-α or IL-1β to regulate osteoclastogenesis (79).
Translational Applications
Systematic approaches to control inflammation through immune
modulation have been applied in different animal models
of periodontal disease with the potential for translational
applications. For instance, the blockade of the complement
cascade at an earlier level, by the inhibition of C3 with AMY-
101 (Cp40), is effective in a non-human primate model of
periodontitis (80). This model is significantly more predictive
of drug efficacy in a clinical setting since complement blockage
inhibits inflammation in naturally occurring periodontitis
(81). In murine models, the local delivery of CCL2 by
control-delivered microparticles promoted the recruitment and
differentiation of M2 macrophages, which in turn prevented
alveolar bone loss (82). Similarly, the administration of CCL22-
releasing microparticles prevented inflammatory bone loss by
inducing the selective chemo-attraction of Treg in both murine
and canine models of periodontitis (63). Rosiglitazone, a
peroxisome proliferator-activated receptor (PPAR)-γ agonist,
induced resolving macrophages with an M2-like phenotype
that reduce bone resorption and enhance bone formation (51).
The treatment with all-trans-retinoic acid or the synthetic
retinoic acid receptor (RAR) agonist tamibarotene (Am80)
improved the Th17/Treg balance and decreased the alveolar
bone loss during periodontitis (83, 84). The treatment with
RvD2 (a resolution agonist) prevented alveolar bone loss by
inhibiting the systemic and gingival Th1-type of response in
P. gingivalis-induced periodontitis (85). In vivo inhibition of
Th17 differentiation by knocking Stat3 or pharmaceutically
inhibiting Rorc in CD4+ T cells led to significantly reduced
alveolar-bone loss (up to 70%), reflecting their critical role
in the induction of bone resorption by producing IL-17 and
expressing RANKL (9). The antibody-mediated neutralization
of APRIL or BLyS substantially diminished the number of
infiltrating B-cells and reduced bone loss during the experimental
periodontitis (65). The adoptive transfer of B10 cells, previously
cultured with P. gingivalis LPS and cytosine-phospho-guanine
(CpG) oligodeoxynucleotides, into mice with P. gingivalis and
ligature-induced periodontitis, showed a significant reduction of
bone loss and gingival inflammation, associated with increased
local IL-10 production (70). Also, the gingival application of
an optimized combination of CD40L, IL-21, anti-Tim1, which
in vitro induces IL-10 production on B10 cells, inhibited
bone loss in ligature-induced experimental periodontitis (86).
Thus, the development of immune-based therapies has been
proven effective in the prevention of bone destruction during
experimental periodontitis in vivo. Current approaches to drug
delivery and local applications of these therapeutic strategies in
humans are being tested.
APICAL PERIODONTITIS
Definition and Pathogenesis of the
Periapical Periodontitis
The infection of periodontal tissues in the periapical area
following the bacterial invasion of pulp in the root canal
system leads to the inflammatory destruction of the periodontal
ligament, radicular cement and alveolar bone, which are
the clinical hallmarks of apical periodontitis. Interestingly,
the pathogenesis underlying the clinical presentation of
apical periodontitis possesses outstanding parallels with that
of periodontitis (87–89). Both conditions are initiated by an
infectious stimulus and share pathological mechanisms of
tissue destruction (chronic and exacerbated immune response
that uncouples tissue balance) as well as the susceptibility
traits and the treatment approach (eradication of the infecting
microorganisms) (87, 90). Indeed, epidemiological data
suggest that there is a correlation between the occurrence
of apical periodontitis and marginal bone loss characteristic
of periodontitis (91), reinforcing the existence of a common
susceptibility profile.
Cellular and Molecular Basis of the
Periapical Periodontitis
Although microorganisms are essential for disease initiation,
their presence is not sufficient to explain the pathologic
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FIGURE 1 | Osteoimmunology of periodontal disease. During periodontitis, the immune response induced by the dysbiotic microbiota enhances the production of
local RANKL by different immune cells types such as Th1, Th17, B cells. Additionally, the increased gingival levels of IL-17 stimulate the membrane-bound expression
of RANKL in osteoblasts and periodontal ligament fibroblasts; this provokes the activation of osteoclast and bone-loss. On the contrary, in health, different immune
cells such as Tregs, Bregs, M2, and Th2 cells promote an anti-inflammatory and pro-anabolic state that sustain the alveolar-bone homeostasis. PMNs, polymorph
nuclear neutrophil; B/P, B and plasma cell.
phenomena that generate inflammatory destruction of the apical
periodontium (92). The presence of a protected reservoir of
microorganisms inside the root canal system precludes their
eradication by immune defense mechanisms, generating a
loop of constant activation and amplification of the immune
response. Without active regulatory or suppressive signals,
this amplification loop of the immune response results
in a constant and exacerbated response, which causes the
progressive destruction of periodontal support (87). This
exacerbated immune response tampers with the normal turnover
mechanisms of periodontal tissue, particularly bone, uncoupling
bone formation from bone resorption leading to a net bone loss.
Conversely, immunoregulatory mechanisms can provide a fine
tune to immune effector mechanisms, resulting in a response
that can control the spread of the infection outside the root
canal system, while limiting the pathological tissue destruction.
The balance shift toward deficient or excessive response can
allow for infection spreading or uncontrolled periapical tissue
resorption (93).
The treatment of apical periodontitis requires the disinfection
of the root canal system and its obliteration with a biomaterial
capable of maintaining a sterile environment and, in some
refractory cases, the surgical elimination of periapical tissues
(94, 95). The absence of reliable means to know in advance if
the endodontic treatment will be successful or not is a critical
weakness in endodontic therapy. Once the apical lesion has
developed, there are no highly sensitive clinical or radiographic
tools to predict if a lesion will acquire an activated phenotype
-and continue to expand to the surrounding tissues- or will
attain an inactive phenotype, resulting in the arrest of its
progression or even remission and healing. Since not all
subjects suffering from an infection of the root canal will
develop apical periodontitis, it is logical to propose that a
susceptibility profile is necessary for the occurrence of the disease
The identification of putative genetic and molecular markers
potentially responsible for the periapical immune-balance might
help to discriminate susceptible or resistant subjects to improve
the treatment outcome prediction (96). Additionally, periapical
lesion development does not follow a linear pattern, alternating
active and inactive phases, like the “bursts” progression model,
described for periodontitis (97, 98). Therefore, the understanding
of host response elements responsible for the switch from
activity to inactivity can also contribute to elucidate the basis of
susceptibility/resistance to lesions development.
From the genetic viewpoint, the overall hypothesis is that
polymorphic variations in critical genes could contribute to
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increased risk to suffer from apical periodontitis. That possibility
is investigated using a case-control approach, based on the
comparison of a group of diseased subjects (i.e., cases) to an
unaffected group of individuals (i.e., controls). However, in the
context of periapical lesions, the use of a healthy population as
control group disregards the classic case-control study definition,
which states that a case-control study is designed to determine
if exposure is associated with an outcome (99). The absence of
the exposure (bacterial invasion of the pulp in the root canal
system) disqualifies the healthy controls to be compared with
susceptible individuals that develop periapical lesions upon the
“exposure.” The study design, therefore, should comprise groups
exposed to the same causal agent required for periapical lesions
development, but with distinct clinical outcomes. The inclusion
of theoretically resistant individuals (i.e., presenting deep caries
without periapical lesions) have been found to improve the
odds of identifying genetic factors that potentially contribute to
increasing the risk to periapical lesions development (100, 101).
A similar approach has been used in chronic periodontitis, with
the use of chronic gingivitis subjects as a theoretically resistant
population (99, 102).
Despite the inherent complexity to genetic association
case-control studies, another useful approach to unravel the
potential influence of genetic variants in apical periodontitis
pathogenesis is to perform correlation analysis between the
different genotypes/alleles and host response markers. For
instance, MMP1-1607 polymorphism (rs1799750) is associated
with increased expression of MMP-1 mRNA. MMPs are a
family of collagenolytic enzymes responsible for the degradation
and remodeling of the extracellular matrix. An increase in the
expression or activation of MMPs without a parallel increase in
their tissue inhibitors mediate numerous pathological processes,
including apical periodontitis (103). In a sample of 326 subjects,
the alternative variant of MMP-1 rs1799750 was associated with
increased risk to suffer from apical periodontitis. Additionally,
the cytokines TNFα, IL-21, IL-17A, and IFN-γ were associated
with augmented transcriptional activity of MMP-1 in apical
periodontitis, favoring its development (104).
Wnt/β-catenin signaling plays an essential role in bone
biology, especially in the differentiation of osteoblasts and
the suppression of bone resorption (105). The Wnt family in
humans consists of 19 highly conserved genes that regulate
gene expression, cell behavior, cell adhesion, and cell polarity
(106). The polymorphic variations on the genes WNT3 and
WNT3A were associated with increased susceptibility to apical
periodontitis, specifically an intronic SNP in WNT3 (rs9890413)
and a promoter SNP in WNT3A (rs1745420). The WNT3
(rs9890413) SNP is in an intronic region and to this date has no
known function, so its putative mechanism of action to regulate
apical periodontitis susceptibility is indefinite. On the other hand,
a functional assays showed that the alternate allele G in the
associated WNT3A (rs1745420), located in the gene promoter,
increased promoter activity by 1.5-fold in comparison to the
ancestral allele C. These findings suggested that this SNP may
have a regulatory role in WNT3A expression and function (data
not published).
The comparison of the gene expression signatures of
periapical lesions with periapical tissues known to experience
bone resorption or bone formation (i.e., in pressure and tension
sides of teeth submitted to orthodontic forces) may allow for the
discrimination of osteolytic activity status. Using this approach,
it was possible to categorize apical granulomas in “active” or
“inactive” according to their molecular profile of RANKL/OPG
mRNA expression (107). Once the activity of the lesion was
defined, it was possible to discriminate host response patterns
associated with each subset. In this context, the inflammatory
signature of 110 apical granulomas (persisting apical lesion
after a technically adequate endodontic treatment, requiring
surgery) and 26 healthy periapical tissues as controls were
characterized (108). The apical granulomas were categorized
as “active” or “inactive” according to the molecular profile
of RANKL/OPG mRNA expression (107). The inflammatory
signature was investigated by the expression of Th1, Th2, Th9,
Th17, Th22, Thf, Tr1, and Tregs cytokines/markers. The cluster
analysis revealed that “active” apical lesions were characterized
by increased expression of TNF-α, IFN-γ, IL-17A, and IL-21,
whereas “inactive” lesions expressed increased levels of IL-4, IL-9,
IL-10, IL-22, and Foxp3. Interestingly, distinct patterns of IFNγ
and IL-17 expression were described in periapical lesions. Lesions
presenting a high RANKL/OPG ratio (active) overexpress IFNγ
and IL-17 compared with inactive lesions. Additionally, active
lesions can be clustered in groups presenting distinct patterns of
IFNγ and IL-17 expression, suggesting that Th1/Th17 cytokines
can drive apical periodontitis development independently (108).
Accordingly, different studies describe that Th1 and Th17
responses can be mutually inhibitory (109). However, the
Th1/Th17 interplay seems to be way more complicated than the
mutually inhibitory activity, suggesting that collaborative and
inhibitory phases may coexist in different disease stages. Also,
cells presenting features of both Th17 and Th1 subsets, including
Tbet and IFNγ expression, have been described in inflammatory
and osteolytic conditions (110).
Therefore, the activity status of apical periodontitis may be
determined by the relative enrichment of different Th subsets.
Indeed, leukocytes subsets such as Th2, Tregs, and MSCs
mediate a natural immunoregulatory response that suppresses
apical periodontitis development. IL-4 (the prototypical Th2
cytokine) was described to induce the expression of CCL22, a
main chemoattractant of Tregs (63). It is noteworthy that Tregs
hallmark products, such as IL-10 and TGF-β, are described to
boost MSCs immunosuppressive properties (111). Therefore,
while all the details regarding the potential Th2, Tregs and
MSCs cooperation remain to be unraveled, the existence of
a protective/regulatory cellular network in inflamed periapical
tissues seems feasible (89, 108).
Impact of Osteoimmunology in the
Periapical Disease
A recent study points to an unexpected potential trigger
of a protective immunoregulatory response (112). While
RANKL has a well-characterized role in the control of
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bone homeostasis, it can also play critical roles in the
regulation of the immune system. Indeed, while anti-RANKL
administration resulted in the arrest of periapical bone loss,
it led to an unremitting pro-inflammatory response and
impaired immunoregulation, restored by Tregs adoptive transfer
(113). Therefore, RANKL seems to be responsible for trigger
immunoregulatory feedback via Tregs induction, which in turn
acts as suppressive elements (113). Notably, RANKL seems to
play a fundamental role in linking the immune system with
bone metabolism. Infiltrating immune cells are an important
source of RANKL, but also resident bone osteoblast produce
and secrete RANKL, most of the time under the regulatory
influence of osteocytes following mechanical or endocrine
stimulus (73, 75).
Despite the lymphocyte-centered paradigm of the most
studies into apical periodontitis pathogenesis in the last decade,
other leukocyte subsets (such as granulocytes) also can play
significant roles in periapical lesion pathogenesis. For example,
we determined that CXCL12 levels increase significantly in
apical periodontitis. CXC ligand 12 (CXCL12 a.k.a. SDF-1) is
a pleiotropic chemokine that regulates the influx of leukocytes
to inflamed sites. In apical periodontitis, CXCL12 proved to be
the primary molecular signal responsible for the recruitment of
mast cells into the periapical inflammatory infiltrate during lesion
development (114). This CXCL12/mast cell axis is significant as
mast cells can secrete a variety of molecular signals and regulate
many diseases (115, 116).
Another major cellular player during the first stages of the
immune response in the pathogenesis of apical periodontitis
is the neutrophil. These cells invade the apical periodontium
in vast numbers and are in the front line of contention of
bacterial infection. Despite being mainly associated with the
direct killing of bacteria and tissue necrosis, neutrophils are also
capable of releasing molecular mediators into the extracellular
compartment and influencing the later stages of the response
(117, 118). Accordingly, a significant increase in heat shock
protein 27 (HSP27) and Serpin Family B member 1 (SERPINB1)
protein levels were identified in apical periodontitis compared
to healthy tissues (119). HSP27 belongs to the heat shock
protein gene family and has an essential role in the inhibition
of apoptosis in thermal and chemical stress, protecting the
cells from injury in hostile environments (120). SERPINB1 is
a potent inhibitor of neutrophil serine proteases and plays
crucial roles in protecting PMN and other cells from apoptosis
(121). The role of another Serpin family member (SERPINE1)
has been demonstrated in the stabilization of apical lesions
(122), thus pointing to a molecular pathway of Serpin family
proteins regulating PMN functions and periodontal destruction
in apical periodontitis. Importantly, this increased expression
of HSP27 and SERPINB1 was compartmentalized to epithelial
cells and infiltrating neutrophils in the inflammatory front
(119). The expression of HSP27 and SERPINB1 was inversely
correlated with markers of acute inflammation and markedly
increased in apical lesion characterized as “stable/inactive.” This
evidence suggests that HSP27 and SERPINB1 could be putative
markers of lesion regression and useful to follow the outcome of
endodontic treatment
Ultimately, most osteoclastogenic signals are controlled by
osteocytes, whether directly by secreting osteoclastogenic signals
or indirectly by entering apoptosis (123–125). The inflammatory
milieu characteristic of apical periodontitis creates the necessary
environment to favor pro-osteoclastogenic signaling and net
bone loss (72). The communication network established
between osteocytes and osteoblast is capable of sensing delicate
environmental changes and react to favoring the bone formation
and resorption (126). The exacerbated and unrelenting immune
response characteristic of apical periodontitis provides plenty
of pro-resorptive signals that tilt the balance in favor of bone
resorption (127, 128).
Taken together, recent findings point to a complex and
multilevel regulatory network that underlies the clinical
presentation of apical periodontitis (Figure 2). Infecting agents
and immune defense mechanisms are in opposing trenches in
an all-out war leading to apical lesion formation or regression.
As in many other diseases characterized by inflammatory tissue
destruction, the regulatory features of the immune system have
a disproportionally important role in the progress and outcome
of the disease. Despite extensive efforts, there is still much to be
investigated and learned before we can develop a comprehensive
molecular model capable of guiding changes in clinical conducts
leading to improved clinical outcomes in the treatment and
management of apical periodontitis.
BIOLOGICALLY-BASED DIAGNOSTICS
AND THERAPEUTICS TO MANAGE ORAL
AND SYSTEMIC HEALTH IN
PERIODONTITIS PATIENTS
Marginal periodontitis and periapical periodontitis are the
most common oral diseases involving alveolar bone loss (129).
Substantial research supports the positive association between
periodontitis and several systemic diseases such as cardiovascular
diseases and diabetes, while growing evidence is unveiling an
analog connection with periapical lesions. Recently, periodontitis
has also been associated with the onset and development of oral
and extraoral cancers, and their fatal outcome (130–132).
The result of periodontitis forms is a prolonged release of
both host-derived inflammatory/collagenolytic mediators (e.g.,
arachidonic acid metabolites, cytokines, nitric oxide [NO],
reactive oxygen species [ROS] and MMPs), and virulence factors
generated by the dysbiotic perio-pathogens and/or endodontic
pathogens in the etiologic microbial biofilm. Though this
response is intended to restrain dissemination, this toxic “brew”
impairs the host’s immune response. The proposed mechanisms
linking periodontitis and extraoral diseases involve the spread of
bacteria from the oral cavity causing damage to other organs, the
increase in inflammatory systemic burden, or an autoimmune
response triggered by oral bacterial species (133–138).
Albeit clinical and radiographic examinations are the gold
standard for the diagnosis of periodontal and periapical diseases,
variations in the inflammatory profile might impact disease
susceptibility and severity at both local and systemic levels
(129, 139). Oral fluids (gingival crevicular fluid/GCF, mouth
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FIGURE 2 | Immunological features of active and inactive periapical lesions. In the periapical environment, the presence of endodontic pathogens and its products
(such as LPS) triggers the host inflammatory immune response. The analysis of gene expression signatures of periapical lesions allows for the discrimination of
osteolytic activity status in “active” or “inactive” according to RANKL/OPG expression ratio. Active periapical lesions are characterized by high RANKL/OPG ratio is an
association with a pro-inflammatory milieu, which includes a high level of IFN-g and IL-17. Distinct patterns of IFNg and IL-17 expression were described in periapical
lesions, suggesting that Th1 and Th17 subsets, described to be mutually inhibitory, can drive apical periodontitis development independently. The presence of PMNs
and mast cells also have been associated with lesion activity. Conversely, inactive lesions are characterized by a low RANKL/OPG ratio is an association with an
anti-inflammatory milieu, which is supposed to involve a cooperative immunoregulatory network composed by Th2 and Tregs subsets, as well by MSCs. The
prototypical Th2 cytokine IL-4 is described to induce the expression of CCL22, a main chemoattractant of Tregs. Noteworthy, Tregs hallmark products, such as IL-10
and TGF-β, are described to boost MSCs immunosuppressive properties. Interestingly, a recent study points to RANKL as an unexpected immunoregulatory
feedback trigger via Tregs induction.
rinse, and saliva samples) obtained non-invasively from the oral
cavity are critical sources for factors and/or biomarkers related
to the metabolic activity of periodontal tissues. Quantitative
point of care (PoC)/chair-side technologies are emerging as
available tools to monitor periodontal conditions, including
orthodontic tooth movement, periodontitis, apical periodontitis,
and peri-implantitis, whereas key inflammatory mediators can
be targeted for therapeutic purposes. Complementary salivary/
oral fluid MMP-8 determinations aid to identify periodontal loss
and inflammation in line with clinically deepened periodontal
pockets, bleeding on probing, and radiographic alveolar bone loss
(140–144). MMP-8, MMP-9, TRAP-5, and MPO demonstrates
very high diagnostic accuracy in GCF for discriminating
periodontitis, apical periodontitis, gingivitis and/or healthy
periodontium, supporting their usefulness for PoC diagnostics
(129, 142). Of interest, oral fluid biomarker analysis has shown
usefulness in extraoral conditions or diseases (141, 142), whereas
GCF placental and inflammatory markers proved the diagnostic
potential for preeclampsia (145) and gestational diabetes mellitus
in pre-symptomatic women (146), revealing new emerging
spectra for oral fluid applications.
Up to now, several studies have explored the associations
between tooth loss, oral infections, CVD and diabetes, and
it is widely accepted that low-grade systemic inflammation,
as measured by CRP and other biomarkers, influences their
development and progression. Currently, there is substantial
evidence supporting that marginal periodontitis imparts
increased risk for future atherosclerotic cardiovascular
disease, in which the exacerbated inflammatory burden
favors atheroma formation, maturation, and exacerbation.
Periodontal treatment can reduce systemic inflammation as
evidenced by a reduction in C-reactive protein (CRP), reduce
the levels of oral fluid and systemic (serum) proinflammatory
biomarkers of tissue destruction and improve endothelial
function and subclinical atherosclerosis, but the evidence is
not yet conclusive (131, 147). Periodontitis also associates
with elevated risk for dysglycaemia and insulin resistance,
as well as incident type 2 diabetes, whereas the latter is also
an essential modifying factor for periodontitis. Evidence
supports that periodontal therapy seems to improve glycemic
control, although studies involving long-term follow-up are
also inconclusive (133). Despite the associations between
endodontic infections, CVD and diabetes have not been
thoroughly explored; emerging evidence sustains an analogous
link (134).
Most available mechanistic studies seeking for an association
between apical periodontitis and the systemic inflammatory
burden lacks adequate control for confounders. Often, a
clinically heterogeneous mixture of acute and chronic forms
of apical periodontitis is included, and participants are older
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than the main risk group, resulting in overall inconclusive
evidence for hsCRP. Few recent studies accounting for these
variables reported early endothelial dysfunction and up-
regulation of pro-inflammatory cytokines, including IL-1,
IL-2, IL-6, reactive oxygen species, as well as asymmetrical
dimethylarginine in serum from young adults with CAP
compared to healthy volunteers (148). Recently our group
demonstrated an association between apical lesions and
cardiovascular risk based on CRP serum levels concentrations
(135), but the systemic effects of endodontic treatment are yet
unknown (134).
Recently periodontitis was proposed as an independent
risk factor for cancer development, such as digestive tract
cancer, pancreatic, lung, prostate, breast, uteri, lymphoma,
and hematological cancer. Moreover, in population-based
studies, periodontitis was strongly linked to cancer mortality,
especially in patients with pancreatic cancer (130, 149, 150).
Studies demonstrate a role of microorganisms such as Human
Papillomavirus (HPV), Epstein-Barr virus (EBV) and P.
gingivalis that could be detected in inflamed periodontal
tissues and might favor cancer initiation at the oral
cavity or distant tissues (151–153). Recently, Treponema
denticola, a virulent proteolytic periodontopathogen, was
found to promote the onset of oro-digestive cancers
(154, 155). Besides oral pathogens, the local and systemic
inflammatory responses associated with periodontitis can
represent an indirect mechanism that could promote cancer
development (130).
Periodontitis derived-systemic low-grade inflammation can
also be readily monitored in serum samples, by measuring
acute-phase proteins such as C-reactive protein, to further
diagnostically assess the risk. hsCRP measurement is especially
recommended in subjects at intermediate cardiovascular risk
to determine the need for treatment (156); hsCRP levels
are also used to evaluate the success of an intervention
such as the metalloproteinase inhibition with sub-antimicrobial
doses of doxycycline to prevent acute coronary syndromes
(MIDAS) (157, 158). In this way, biomarker’s utility becomes
clinically practical with the current availability of PoC chair-
side biomarker analysis of oral fluids & serum, and host-
modulation therapies such as non-antimicrobial doxycycline
medications (Periostat R©, now generic; and Oracea R©) as
pleiotropic MMP-inhibitors, and others such as omega-3 fatty
acid derivatives (e.g., docosahexaenoic acid), i.e., the resolvins
(Figure 3) (159–161). Thus, recently-developed strategies of
personalizing the use of “host-modulation therapy,” when
indicated by modern PoC chair-side diagnostic tests (140,
144), may significantly enhance the beneficial outcome of
both the commonly-used oral therapy (scaling & root planing,
and oral hygiene instruction) and its impact on the overall
medical health of the patient. Further evidence of the need
for modern, biologically-based diagnostics and therapeutics to
manage the oral/systemic health of the patient is continuously
emerging. These findings reinforce the view that modern,
biologically-based oral-systemic health management requires
a “two-pronged strategy” including diagnostic monitoring in
oral fluids biomarkers, and optimally therapeutic suppressing
these mediators with “host-modulation therapy” combined with
microbial biofilm management. Both strategies are currently
available to the dental clinician as the result of long-term and
substantial basic and translational research.
BONE SARCOMAS (BS) AFFECTING THE
MAXILLOFACIAL REGION
Definition and Epidemiological Impact of
Bone Sarcomas
Bone Sarcomas (BS) are rare primary mesenchymal bone
tumors (<0.2% of malignant tumors of EUROCARE database),
including osteosarcoma (OS), Ewing sarcoma (ES) and
chondrosarcoma (CS) (162). BS affects more frequently the
appendicular skeleton (lower limbs) than the craniomaxillofacial
skeleton. In this area, maxilla and mandible are more affected
bones over cranial bones (163). Thus, maxillofacial (MF) OS
(MFOS), ES (MFES), and CS (MFCS) are considered malignant
tumors of the maxillofacial region according to the 4th edition of
the World Health Organization Classification of head and neck
tumors (164). Here, we will focus specifically on MFOS, MFES,
and MFCS, highlighting the role of immune response on their
pathophysiology and, also, revising experimental approaches
for therapy.
Maxillofacial Osteosarcoma (MFOS)
MFOS represent <10% of the total OS (165). Compared
with the appendicular OS, which peaks in the 2nd and sixth
decade, MFOS peaks in the 3rd decade (162, 163, 165).
Typically, MFOS arise from the cancellous compartment rather
than bony surfaces. MFOS affects the alveolar ridge of the
mandible and posterior area of the maxilla (163, 166). MFOS
can be categorized according to the predominant matrix as
an osteoblastic, fibroblastic, chondroblastic, telangiectatic, or
osteoclastic type (163, 165). At the X-ray imaging, MFOS appear
as either as the osteolytic form with undefined margins or, the
osteoblastic form, showing a sclerotic and sunburst structure
caused by radiated bone spiculae (163).
Maxillofacial Ewing Sarcoma (MFES)
MFES is 1–4% of all ES which peak in both the first and
second decades mainly in white Caucasian people, affecting
equally both sexes (163). MFES is an aggressive, hemorrhagic,
and rapidly metastatic malignant tumor affecting naso-orbital
bones. MFES are characterized by an irregular lesion combining
sclerosis and lucent zones compromising cortical bone. MFES
also show the characteristic onion peel appearance and sunburst
new bone formation, which correspond to periosteal osteogenic
reaction (163).
Maxillofacial Chondrosarcoma (MFCS)
It accounts for 2% of all CS with a peak incidence during
the 4th to fifth decades with a male predilection (ratio 2.4:1).
It affects mostly the skull base, maxilla, and less frequent
the orbit and, cartilage of the nasal septum. MFCS can be
observed after malignant and benign diseases such as OS,
fibrosarcoma, Paget disease, and fibrous dysplasia (163, 167).
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FIGURE 3 | Osteoimmunology at the osteosarcoma (OS) niche. Tumor-Associated Macrophages (TAMs), Tumor-Infiltrating Lymphocytes (TILs) and Mesenchymal
Stem cells (MSCs) regulate osteosarcoma cells (OSCs) proliferation, tumor mass progression, and metastasis. The RANK/RANKL signaling leads to both OSCs
progression and increased osteoclast activation and bone loss in the OS niche.
Histologically, chondrosarcoma of the craniofacial region can
be divided into (a) the conventional subtype with myxoid
and/or hyaline components, the most common form, is slow
growing, and rarely metastatic; (b) the aggressive mesenchymal
and dedifferentiated subtype, more aggressive and tends to
metastasize and; the clear cell subtype, extremely rare (163).
High-grade CS can induce metastasis, but local recurrence of
curettage is a common feature of such tumors. Since the vast
majority of literature describing the pathophysiology of BS focus
on the non-maxillofacial OS, we will base our work upon these
recent findings.
These three entities result from the disruption of
differentiation of Mesenchymal Stem Cells (MSCs) into
bone and cartilage cell lineages (168). In bone homeostasis,
MSCs differentiate into stromal cells, which will contribute to
both the hematopoietic and the skeletal niches (168, 169).
At the skeletal niche level, stromal cells will activate
transcription factors such as Runx2 to follow the osteogenic
path to become functional osteoblasts or, Sox9 to follow
the chondrogenic pathway to become cartilage cells
(168) (Figure 3).
BS results from the interaction of both OS cells (OSCs),
cancer stem cells, and their niche. OSCs are the malignant
counterpart of osteoblasts. OSCs are mesenchymal-derived cells
subjected to an initial oncogenic event altering the commitment
from a mesenchymal cell toward an osteoblast by a mutation
(e.g., p53 and Rb) and/or aberrant Hedgehog and Notch
signaling (168, 170). Within the tumor mass, cells exhibit
high heterogeneous profiling that can be partly explained
by the presence of cancer stem-like cells (CSCs), the clonal
evolution of OSCs and the high heterogeneity of the local tumor
microenvironment (168, 170). These cells are characterized by
its self-renewing property, and they are proposed as responsible
for tumor progression, resistance to chemotherapy, and initiate
metastasis (168, 171). Based on the “seed and soil’ theory of
Paget, it is now well-recognized that OS, like other cancers,
requires an adequate localmicroenvironment for its development
(168, 171). This specialized microenvironment provides all
metabolites and regulates the self-renewal process of CSCs
(171). Interactions between OSCs, CSCs, and its niche may
determine OS progression or dormancy and, potential drug
resistance (171, 172).
Cellular and the Molecular Immune Basis
of Bone Sarcomas
Some clinical studies correlate survival rates of OS
patients with both immune markers and the immune cell
(lymphocyte/macrophage) ratio (173, 174). However, the
role of the immune system in OS development remains still
misunderstood. The relationship among OS niche and immune
response may be explained by the fact that OSCs (and also, bone
cells) are surrounded by bone marrow cells occupying the same
bone marrow space. Within this space, hematopoietic precursors
give rise to the immune cell population, lymphoid, myeloid
cells, and mast cells. These cells will regulate both innate and
acquired immune responses (173). Consistently; an immune
infiltrates composed by monocyte/macrophages/dendritic cells
and T-lymphocytes have been identified in OS tissues (173, 174).
Although B-lymphocyte and mast cells are less represented in
the OS tumor mass, they are far more distributed in the interface
bone-tumor. Both lymphocytes and mast cells are essential
sources of RANKL, becoming key players in the activation of
osteoclasts, and then contributing to the osteolytic feature of
OS (173, 174).
Macrophages are essential cells participating in bone
homeostasis (173, 174). Macrophages, located in the vicinity
of the tumor, are known as Tumor-Associated Macrophages
(TAMs) (168). TAMs control local immunity, angiogenesis,
and regulate tumor cell migration and invasion (168). Also,
TAMs participate in the seating of cancer cells at the metastatic
site by modeling the permissiveness of the host-tissues (168).
TAMs are composed by a large variety of subpopulations
which have been classified initially in M1 and M2 subtypes
according to their differentiation and activities. M1, the pro-
inflammatory macrophage subset, are classified as anti-tumor
cells and associated with excellent survival rates, and M2, the
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FIGURE 4 | Immune response and bone crosstalk during temporomandibular joint osteoarthritis. The sustained functional overload that exceeds the joint adaptive
capacity can induce dysfunctional remodeling. This dysfunctional remodeling is characterized by increased oxidative stress, due to hypoxia/reperfusion effect, and
higher levels of catabolic enzymes that degrade the fibrocartilage extracellular matrix and induce chondrocyte apoptosis. The molecular products derived from
cartilage breakdown (e.g., LMW-HA or PG) can trigger the immuno-inflammatory response by interacting with APCs and finally resulting in the activation of Th17
lymphocytes and the RANK/RANKL/OPG axis, leading to subchondral bone resorption. The normal joint load of the TMJ, such as static loading during swallowing or
teeth clenching, induces an adaptive functional remodeling of joint tissues and promotes fibrocartilage healing. HYAL, hyaluronidase; LMW-HA, low molecular weight
hyaluronan; NOS, nitric oxide; OPG, osteoprotegerin; ROS, reactive oxygen species; sRANKL; soluble receptor activator of nuclear factor-kappa B ligand; APCs,
Antigen presenting cells.
anti-inflammatory macrophage subset, as pro-tumor regulators
(168, 173, 174). Thus, in OS patients, a TAM-M1 predominant
ratio over TAM-M2 was associated with better survival rates
and the opposite, with poor prognosis (168, 173, 174). These
associations may be explained by an immunosuppressive effect
on intra-tumor T-lymphocytes, and pro-angiogenic effect
exerted by TAM-M2 observed both preclinical models of OS and
metastatic patients (168, 173, 174).
T-infiltrating Lymphocytes (TILs) are the second more
prevalent infiltrated cell type in OS tissues and OS metastasis
(174). Studies showed that selected subpopulations of T-cells
(CD8+/FOXP3+) exhibit high reactivity again tumor cells
compared with non-infiltrating lymphocytes (175). Thus, OS
patients with elevated CD8+/FOXP3+ -ratio had better survival
rates confirming the immunosuppressive role of TIL in OS
pathogenesis (175, 176). TILs have higher cytotoxic properties
again OS cells compared with circulating T-cells; however, OSCs
secrete immunosuppressive molecules preventing the activation
of TILs on the tumor site (175).
Beside immune cells, Mesenchymal Stem Cells (MSCs)
have been reported as an essential regulator of OS behavior
(177). Indeed, both bone and the bone marrow niche are
rich in MSCs that are closely located to OS cells (178).
Several studies demonstrated that MSCs establish active crosstalk
with OSCs controlling OS progression and/metastasis (178).
MSCs and early developed pre-osteoblasts communicate with
OSCs by secreted vesicles containing mRNA, proteins, and
miRNA modulating OSCs proliferation and stemness (e.g.,
ability to form sarcospheres, expression of stem-associated
genes) (179). Reciprocally, OSCs are able to educate MSCs
by tumor-secreted extracellular vesicles turning MSCs into
OS extracellular vesicle-educated MSCs. These cells promote
tumor progression and/or metastasis via secretion of IL-
6, TGF-β and IFN-γ and by inhibiting T, B and NK cell
proliferation (173, 174).
Impact of Osteoimmunology in
Bone Sarcomas
Bone remodeling is controlled by osteoblasts and osteoclasts,
which are responsible for bone formation and resorption,
respectively. Bone remodeling is regulated by the
RANKL/RANK/OPG triad (180). RANKL expressed as a
membranous or secreted form by stromal and osteoblastic cells
which binds to RANK, a transmembranous receptor expressed
by pre-osteoclast. Their interaction leads to the activation of pro-
osteoclastic genes (e.g., NFATc1, cathepsin K, TRAP), osteoclast
differentiation (osteoclastogenesis) and then, bone resorption
(180, 181). OPG is secreted by stromal and osteoblastic cells
acting as a soluble decoy receptor for RANKL, leading to the
inhibition of osteoclastogenesis and bone loss (180, 181).
In the OS context, the fact that RANK usually is not expressed
by osteoblastic cells and the recognition of RANK+ OSCs have
been long debated. However, human data andmost of established
OSC lines confirm the expression of RANK by OSC, proposing
the interaction of RANK with its ligand (RANKL) as a critical
contributor in OS pathogenesis (181). In this line, a preclinical
genetic model of aggressive OS in a RANKL invalidated mice
showed the complete blocking of OS development, confirming
the critical role of RANK/RANKL signaling into OS progression
(182). Moreover, human data analyzing OS tissues from patients
with or without metastatic status showed that RANK is expressed
in both groups, meaning that RANK expression is not related
with the metastatic status, becoming a potential predisposing
factor. However, the overexpression of RANKL and the lower
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OPG/RANK ratio in tumors from metastatic patients lead to
hypothesize that the RANKL available in the OS niche is a
significant driver to tumor progression and metastasis in OS
patients (181). Taken these findings together, strongly support
the use of RANKL blockers as a therapeutic approach for OS
progression to a metastatic status (181).
On the other hand, the RANKL/RANK/OPG triad has been
associated with the pathogenesis of OS by regulating both the
osteoclastic activity and, immunoregulatory effects (180, 181).
However, the real contribution of osteoclasts to the pathogenesis
of OS remains still controversial. Some authors propose that
the RANKL-activated osteoclasts might exert a pro-tumoral
function in the early stage and on the contrary, a pro-bone
remodeling/anti-tumoral effect in the later stage of OS (180,
181). Moreover, osteoclasts may modulate immune response
promoting an immunogenic CD4+ T cell response upon
inflammation. Taken together, osteoclasts can be considered as
essential regulators of OS growth and progression through either
their resorptive or their immune functions (180, 181).
Bone Sarcomas and Immune-Based
Therapeutic Approaches
In contrast to CS for which the conventional therapy is based
on surgery with adequate margins, current treatments of ES
and OS associate chemotherapy and surgery. Chemotherapy
lines combined a minimum of three cytotoxic agents among
doxorubicin, cisplatin, methotrexate, and ifosfamide (168).
Unfortunately, most conventional therapies used results in
limited therapeutic responses, and new approaches are urgently
needed explaining the high number of clinical trials with new
drugs for rare cancers including immune modulators, check-
point inhibitors and tyrosine-kinase inhibitors (168, 174, 183,
184). Among immune regulators, an activator of macrophages
such as muramyl tripeptide phosphatidylethanolamine (MTPPE)
showed therapeutic efficacy in the metastatic OS. Trabectedin,
a cytotoxic agent, could be attractive to treat sarcomas thanks
its effect on macrophage differentiation toward M1 subtypes
and targeting of PD1/PDL1 may be promising therapy by
disrupting the communications between cancer cells and
immune protagonists (183, 184). However, future therapeutic
development will require a better characterization of the critical
molecular network involved in the differentiation of BS cells and
their microenvironment that should lead to the identification of
new therapeutic targets and will allow better stratification of the
patients enrolled in clinical trials (183, 184).
OSTEOARTHRITIS OF THE
TEMPOROMANDIBULAR JOINT
Definition and Pathogenesis of the
Osteoarthritis of the
Temporomandibular Joint
Degenerative joint disease (DJD) is characterized by the
progressive breakdown of articular cartilage, variable degrees
of synovial inflammation, and pathological remodeling of
subchondral bone (185, 186). Osteoarthritis (OA) is considered
the most common form of DJD, affecting approximately 15% of
the world population, and a leading cause of pain and disability
(187, 188). Although, it mainly affects load-bearing synovial
joints, such as the knee, hip, spine, and finger, other joints such
as the shoulder or temporomandibular joint (TMJ) could also
be affected (189). The TMJ is an exceptional synovial joint that
connects the jawbone to the skull and, compared to the knee
joint, it is exposed only to limited load-bearing forces (189).
It has different morphological, functional, biomechanical, and
biological features in comparison to other synovial joints (190).
In the knee joint, hyaline cartilage covers articular surfaces, while
in the TMJ, the articular lining is covered by fibrocartilage, which
is surrounded by an angiogenic microenvironment and is softer
than hyaline cartilage (186, 191). Thus, TMJ osteoarthritis (TMJ-
OA) should not be considered as a common joint disease, but
rather a unique one.
Although different factors such as systemic illnesses,
developmental abnormalities, disc displacement, micro-trauma,
and parafunction have been associated with the etiology of
TMJ-OA, functional overload has been described as its main
etiologic factor (28, 189, 192, 193). Articular remodeling
is an essential biological process that responds to normal
functional loading and ensures the joint’s homeostasis (189).
However, excessive or unbalanced mechanical loading in the
TMJ can induce dysfunctional articular remodeling, leading to
degenerative changes (189). Two kinds of mechanical loading
occur in the TMJ: Static loading, which occurs during teeth
clenching, jaw bracing, and swallowing; and dynamic loading,
which occurs during tooth grinding, jaw thrusting, talking, and
chewing (194). For instance, the static loading applied during
forced mouth opening for 1 day increases the expression of
Dickkopf factor-3 (Dkkf-3), an antagonistic non-canonical
member of the Wnt family, in the cartilage surface and induces
the synthesis of type II and type X collagen in the inner
fibrocartilage layers; thus, promoting anabolic effects over
the mineralized and unmineralized condylar cartilage (195).
Nevertheless, when the same force was applied for 1 week,
catabolic effects and several degenerative lesions were observed
in the TMJs (196, 197).
Similarly, in vitro experiments demonstrated that the effects
of loading forces are time-dependent. After 24 h of dynamic
compressive loading over condylar chondrocytes, the expression
levels of aggrecan, type I and type II collagen increased, possibly
as an adaptation attempt; though, after 48 h these expression
levels decreased significantly, showing a catabolic effect of
prolonged loading (198). Furthermore, compressive forces also
promote osteoclastogenesis through the increased expression of
RANKL in synovial cells (199). In brief, light forces induced
with a mouth opening protocol demonstrated an anabolic effect
over TMJ, while massive forces induced a catabolic effect over
joint tissues (200). Dynamic overloading forces in a TMJ-OA
mice model disrupted the metabolism of hyaluronan (HA), one
of the central extracellular matrix (ECM) glycosaminoglycans
(GAGs) of the TMJ fibrocartilage (200). In this study, the
sustained loading forces significantly decreased the expression
levels of hyaluronan synthase (HAS) 2 and 3 and increased the
expression levels of hyaluronidase (HYAL) 2 and KIAA1199,
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an HA binding protein that facilitates the degradation of HA
in articular cartilage (200). Interestingly, low-molecular-weight
fragments of HA (LMW-HA) can act as a damage-associated
molecular pattern (DAMPs), activating antigen presenting cells
and initiating the immuno-inflammatory response (201, 202).
Cellular and the Molecular Immune Basis
of the Osteoarthritis of the
Temporomandibular Joint
Many contributing factors have been described in the progression
of bone changes during TMJ-OA, including genetic factors,
female hormones, catabolic enzymes, and inflammatory
mediators (203). Although inflammation has considerable
importance in the progression of TMJ-OA, it is classified
as a “low-inflammatory arthritic condition” as opposed to
rheumatoid arthritis (RA), which is considered as a “high-
inflammatory condition” (204). Recent studies suggest that
OA is an inflammatory disease, at least in certain patients, and
that synovial inflammation is accompanied by immune cells
infiltration, similarly to RA (205–207). Of these immune cells,
macrophages and T lymphocytes are the most abundant cell
types that infiltrate the synovia during TMJ-OA, representing
approximately 65% and 22% of the total immune cells,
respectively (208). Furthermore, several inflammatory cytokines
and mediators are increased in the synovial fluid of TMJ-OA
affected patients, such as IL-1β, IL-6, IL-17, IFN-γ, TNF-α,
prostaglandin E2 (PGE2), and chemerin, suggesting a role of
the immuno-inflammatory response during the pathogenesis of
the TMJ-OA (209–213). In addition to metabolic or mechanical
factors, chronic inflammation induces early damage of the
cartilage and consequently initiates biomechanical changes in
hard and soft tissues of the joint (214). Thus, the low-grade
inflammation present in OA is a result of the interactions
between the immune response and local factors, such as tissue
breakdown and metabolic dysfunction (215).
The inflammatory response to trauma, hypoxia-reperfusion
injury, or chemical-provoked wound typically occurs in the
absence of microorganisms; therefore, it has been called “sterile
inflammation” (216). The first step of sterile inflammation
requires the presence of endogenous molecules released during
tissue or cellular injury, which can act as DAMPs able to
trigger the immuno-inflammatory response (216). DAMPs can
be molecules derived from necrotic cell death, such as high-
mobility group box 1 (HMGB1), heat shock proteins (HSPs), or
purine-derivedmetabolites (e.g., ATP); or fragments ofmolecules
derived from the breakdown of the ECM, such as fragments of
heparan sulfate, byglican, or HA (e.g., LMW-HA) (215). At initial
stages of TMJ-OA, increased local oxidative stress induces the
fragmentation of HA in the synovial fluid and fibrocartilage (217–
219). The oxidative stress could increase due to direct mechanical
trauma, by homolytic fission, or due to hypoxia-reperfusion, and
the following non-enzymatic release of reactive oxygen species
(ROS) (217, 218). The molecular weight of HA decreases and
LMW-HA accumulates within the joint milieu as the disease
progresses leading to an increase of joint friction due to the
reduction of the chondroprotective and boundary lubrication
originally provided by HA (219, 220). Furthermore, LMW-HA
can trigger the immune response by interacting with the toll-
like receptor (TLR)-2 or TLR-4 expressed in antigen presenting
cells (221). TLR activation during OA has been associated
with the development of synovitis, cartilage degeneration, and
disease susceptibility (222). Using an animal model of TMJ-
OA, Kong et al. demonstrated that synovial inflammation
changes are related to increased TLR-4 activation and enhanced
IL-1β production (223). This synovial inflammatory reaction
characterized by the increased levels of IL-1β induced by TLR-
4 stimulation depends on the phosphorylation of p38 during
the mitogen-activated protein kinase (MAPK) signaling cascade
and culminates in the activation of nuclear factor-κB (NF-κB)
or nuclear transcription factor activation protein-1 (AP-1) (224).
Synovitis is frequently observed during the progression of TMJ-
OA (225, 226). The lining layer of synovium is mainly composed
of fibroblast-like cells and macrophage-like cells (227). These
resident cells play a vital role in the immuno-inflammatory
response and bone metabolism during OA by producing several
inflammatory mediators that enhance the breakdown of joint
tissues (228, 229). Synovial fibroblasts (SF) have the ability to
transduce IL-17 signals by expressing different variants of the IL-
17 receptor (IL-17R) (227). In response to IL-17A, SFs of the TMJ
up-regulate the expression levels of the chemokines CXCL1, IL-
8, and CCL20, a specific chemoattractant of Th17 lymphocytes
(227). IL-17A also induces increased production of IL-6 by SFs
of the TMJ (227), and IL-6 favors the Th17 cell differentiation
and promotes osteoclastogenesis and bone resorption (230, 231).
Thus, the increased levels of Th17-related chemokines and
cytokines produced by SFs of the TMJ stimulated by IL-17A
could be related to bone loss and OA progression (227).
In other synovial joints, RANKL is highly expressed on
SFs (232), while in TMJ synovium, RANKL is detected in the
cytoplasm of synovial lining cells, endothelial cells, and SFs (233).
A recent study using Tnfsf11flox/1 Lck-Cre mice, which lack
RANKL expression in T lymphocytes, demonstrated that the
absence of RANKL-producing T cells does not protect against
osteoclastogenesis and bone resorption (234). On the other hand,
the deletion of RANKL on SFs using Tnfsf11flox/1 Col6a1-
Cre mice was protective against osteoclastogenesis and bone
loss, thus demonstrating that SFs are the primary RANKL-
expressing cells, and responsible for the osteoclast formation and
bone resorption during joint inflammation (234). Interestingly,
TMJ chondrocytes affected by chondral degradation, may also
promote osteoclastogenesis by increasing the RANKL:OPG ratio,
ultimately resulting in a subchondral bone loss (235).
LMW-HA is a potent activator of APCs, in particular,
dendritic cells (DCs), through the interaction with the complex
TLR-4/Cluster of differentiation (CD)44/Myeloid differentiation
protein (MD)-2 (236, 237). LMW-HA induces an immuno-
phenotypic maturation of DCs through the up-regulation
of CD44, CD83, CD80/86, intercellular adhesion molecule-1
(ICAM-1), and the major histocompatibility complex (MHC) II
(238). Furthermore, DCs exposed to LMW-HA increase their
capacity to stimulate alloreactive T lymphocytes to secrete IL-
12, IL-1β, and TNF-α (238). Apart from that, LMW-HA could
act as a co-stimulatory molecule during antigen presentation by
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interacting with CD44 and could also promote the activation
and polarization of T lymphocytes (239). The stimulatory effects
of LMW-HA over DCs are mediated by the TLR-4 complex
signaling pathway, including the phosphorylation of p38 and
p42/p44 MAPK and the consequent nuclear translocation of NF-
κB (237). LMW-HA also increases the migratory capacity of DCs
and stimulates its trafficking toward the draining lymph nodes
(240). Moreover, LMW-HA can induce the polarization of DCs
to conventional type 1 (cDC1) and type 2 (cDC2) subsets, by
increasing the expression levels of their specific transcription
factors interferon regulatory factor 4 (IRF4), neurogenic locus
notch homolog protein 2 (NOTCH2), and basic leucine zipper
ATF-like transcription factor 3 (BATF3) (241). Thus, cDC1
produces TNF-α and cDC2 produces IL-6 and IL-23, inducing
the selective differentiation and activation of Th1 and Th17
lymphocytes (242, 243).
Peripheral Th lymphocytes are involved in the pathogenesis
of OA (244). T lymphocytes from OA patients can recognize
peptides presented by APCs such as the amino acid regions 16–
39 and 263–282 located in the G1 domain of human cartilage
proteoglycan aggrecan (PG) (245). The recognition of these PG
epitopes enhances the proliferation of OA-derived T lymphocytes
and increases the production of cytokines, IL-1β, IL-6, IFN-
γ, and TNF-α, and CC-chemokines, CCL-2, and CCL-3 (245).
Increased expression of the Th1/Th17/Th22 cytokines IL-1β, IL-
17, and IL-22, chemokines CCL5, and CCL20, and chemokines
receptors CCR5 and CCR7 have been detected in synovial cells
of TMJ-OA affected patients (212, 246). Further, the increased
levels of IL-1β, IL-17, and IL-22 significantly correlate with the
enhanced RANKL expression and immunological signs of bone
degeneration (246). Moreover, the synovial fluid obtained from
TMJ-OA affected patients induces significantly more osteoclast
maturation and activity in comparison to synovial fluid obtained
from controls (246).
Although both Th1 and Th17 cells are involved in the
etiology of OA, it has been reported that the IL-23/IL-17
axis is more critical than the IL-12/IFN-γ axis in the onset
of the disease (247–249). Analyses of blood samples obtained
from OA affected patients, and healthy donors showed a
significantly higher percentage of activated CD4+ T cells
and Th17 lymphocytes in the OA group, while there were
no differences between the percentages of Th1 and Th2
lymphocytes among the studied groups (250). Further, increased
numbers of Th17 cells have also been detected in the OA
synovial membrane (251). An osteoarthritic joint milieu with
low levels of TGF-β but high levels of IL-12 induces the
plasticity of Th17 lymphocytes to an intermediate phenotype
between Th1 and Th17 lymphocytes known as Th17/1 cells.
These cells are characterized by an increased expression of
the transcription factors retinoic acid-related orphan receptor
C2 (RORC2), and T-box expressed in T cells (T-bet) and
production of the cytokines IFN-γ and IL-17 (252). Indeed, in
OA patients, both peripheral blood and synovial fluid frequencies
of Th17/1 cells are significantly increased in comparison to
healthy subjects or even rheumatoid arthritis patients (253).
Additionally, the enrichment of Th17/1 cells in OA patients
is higher in synovial fluid than serum (253). These findings
suggest that Th17/1 cells could be a Th subset with a particular
role during OA and; thus, need to be further evaluated
in TMJ-OA.
Higher expression levels of IL-17 have been reported in
either synovial membranes or synovial fluid of TMJ-OA affected
patients (212, 246, 254, 255). IL-6, a key cytokine involved in
Th17 polarization, is also increased in the TMJ-OA affected
patients (256). In vitro experiments have demonstrated that
IL-17A promotes synovial hyperplasia, synoviocyte invasion,
cartilage breakdown, and angiogenesis (257–260). Using SFs
isolated from patients with TMJ disorders, Hattori et al.
determined that IL-17A upregulates the expression of IL-6,
CXCL1, IL-8, and CCL20, in a dose- and time-dependent
manner, promoting T lymphocyte chemoattraction toward the
TMJ synovial tissues (227). However, the central role of the Th17
lymphocytes during the pathogenesis of the joint disorders is
related to its RANKL-producing osteoclastogenic function (261).
Impact of Osteoimmunology in the
Osteoarthritis of the
Temporomandibular Joint
Different types of cells orchestrate the physiological remodeling
process within the TMJ bone microenvironment. As mentioned
before, osteoclasts and osteoblasts are the primary effector cells
involved in the bone resorption and formation, respectively, in
the articular subchondral bone. In this molecular-and-cellular-
regulated process, however, the contribution of other cell types,
such as osteocytes, has been considered. Osteocytes are a group
of cells which differentiate from osteoblasts, that during the
formation of mineralized tissues are left embedded within the
bone matrix, and further contribute to the regulation of bone
metabolism (262). Even though, under physiological conditions,
osteoblasts are considered as the primary source of RANKL
for the RANKL-induced osteoclastogenesis and consequent
osteoclast-mediated subchondral bone remodeling; osteocyte-
specific RANKL-deficient mice (Tnfsf11flox/1 Dmp1-Cre or
Tnfsf11flox/flox Sost-Cre mice) present a similar osteopetrotic
phenotype than RANKL-null mice; thus, demonstrating the
importance of osteocytes as a primary source of RANKL (5, 263).
Moreover, by using a high-purity isolation method for osteocytes
and osteoblasts, Nakashima et al. evidenced that osteocytes have
a stronger ability to induce and support osteoclastogenesis than
osteoblasts, through higher Tnfsf11 (encoding RANKL) mRNA
expression and RANKL production (5). Apart from that, the
authors demonstrated that the absence of RANKL in T cells is
not critical for bone metabolism in physiological conditions (5).
Osteocytes also actively release RANKL in response to
mechanical stress (5). Indeed, osteocytes contact osteoclast
precursor cells and mature osteoclasts through long dendrites
that reach the bone surface, which enable direct cell-cell
interaction by membrane-expressed factors released in response
to load forces, such as RANKL (264). A mechanical stress
experiment with MLO-Y4 osteocyte-like cells revealed that
Tnfsf11 expression is remarkably induced by mechanical strength
(5). In fact, during the application of orthodontic forces for
bone remodeling-dependent tooth movement, osteocytes were
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the primary source of RANKL in response to compressive
forces, thus promoting osteoclastogenesis and bone resorption
(265). Conversely, increased loading forces during mastication
induced by a hard diet in mice showed an increase in the
osteocyte-mediated bone formation, through an increment of
the levels of insulin-like growth factor (IGF)-1 and thus,
promoting osteoblastogenesis (266). Therefore, the osteocyte
response to mechanical load could drastically differ between the
physiological context and the pathological scenario during TMJ-
OA. Indeed, osteocytes adjacent to sites of bone microdamage,
as occurs in subchondral bone during the advanced stage of
TMJ-OA, undergo apoptosis; whereas osteocytes adjacent to
this apoptotic cells upregulate the expression of osteoclastogenic
and immunogenic signaling molecules, such as ATP, membrane-
derived peptides, chemokines, vascular endothelial cell growth
factor A (VEGFA), and RANKL (262). Besides, osteocytes
exposed to extra-cellular matrix molecules derived from TMJ-
OA subchondral bone osteoblasts showed decreased levels
of maturation and increased levels of apoptosis due to a
decrease in the integrin-β1 expression, in comparison with extra-
cellular matrix molecules derived from normal subchondral bone
osteoblasts (267). This suggests that the pathological behavior
of osteocytes in response to the mechanical overload during the
progression of TMJ-OA could be due to molecular and cellular
changes occurring in the joint microenvironment.
The RANKL:OPG ratio is increased in synovial fluid
obtained from TMJ-OA patients, mainly due to the increased
levels of RANKL together with the decreased levels of OPG
detected in the joint microenvironment (212, 268). The
secretion of IL-17 by Th17 lymphocytes enhances the RANKL
production by osteoblasts, osteocytes, and SFs and activates
the production of other osteoclastogenic cytokines, such
as TNF-α, IL-1β, and IL-6 by synovial macrophages (269).
Thus, the accumulation of Th17 lymphocytes in synovial
tissues may contribute to subchondral bone resorption by
stimulating the RANKL-mediated osteoclast activity (270).
Kikuta et al. using intravital multiphoton microscopy,
have demonstrated that Th17 but not Th1 lymphocytes
preferentially adhere to mature osteoclasts and that low
levels of RANKL secreted by mature osteoclast-adhered
Th17 lymphocytes could induce the rapid conversion from
moving-non-resorptive to static-bone-resorptive osteoclast
phenotype in bone (271). Besides, using a mice model of
primary hyperparathyroidism, it was described that the
osteocyte-mediated RANKL production induced by Th17-
derived IL17A/IL17RA interaction is critical for the bone
catabolic activity, revealing another potential mechanism of
subchondral bone loss induction by Th17 cells during TMJ-OA
(74). Altogether, these studies demonstrated a pivotal role for
Th17 lymphocytes in the osteoimmunology of the TMJ-OA,
through the modulation of the osteoblast/osteocyte/osteoclast
activity (Figure 4).
Overall, the evidence presented above shows that
TMJ-OA could be considered a chronic mechanically
induced and immuno-inflammatory-mediated disease,
mainly due to the continuous production of DAMPs
during joint tissues destruction, particularly LMW-HA,
the activation of a Th17-pattern of immune response and
the consequent RANKL-mediated and osteoclast-induced
bone resorption.
Translational Applications
For the diagnosis of the TMJ-OA, four criteria are usually
used: Joint noises, chronic joint pain, joint cramping during
movements of the jaw, and degenerative bone deterioration
detected through imaging (111, 214, 272). However, these criteria
are only observable when the disease has been established,
and tissue damage has occurred; so these gold-standard criteria
do not allow early symptoms detection to prevent or stop
the progression of TMJ-OA. In addition, when the diagnosis
has been made, the analysis of treatment success is based on
exactly the same criteria and, in older adults, these criteria are
unreliable, due to the subjective component of clinical symptoms
and the involuntary movements that many individuals present,
which diminish the sharpness of the images and in some cases
making their contribution, as a complement to the diagnosis,
uncertain (273).
Several research groups have proposed to incorporate
competing molecular strategies that could allow the early
diagnosis of TMJ-OA and the evaluation of its therapeutic success
(256, 273–281). In this sense, the determination of molecular
mediators associated with the inflammatory and destructive
articular tissue processes characteristic of TMJ-OA is convenient;
however, nowadays, there are no registered initiatives focused on
the development of an alternative solution complementary to the
current standards for the diagnosis of the disease.
In this sense, the validation of a diagnostic strategy based
on the identification of a panel of detectable biomarkers in the
synovial fluid of the TMJ and complementary to the traditional
clinical-imaging methods of diagnosis of TMJ-OA is feasible.
An ideal diagnostic panel should incorporate osteoimmunology
markers. In this way, the identification of molecular mediators
associated with the differentiation and activity of osteoblasts,
osteoclasts and/or osteocytes, as well as cytokines (IL-1β, IL-6,
IL-17, IL-12, and TNF-α), MMPs (MMP-8 and MMP-9), and
RANKL, could be proposed as potentially sensitive and specific
biomarkers to detect early degenerative changes in the TMJ.
CONCLUSIONS
The understanding of the immune-mediated bone destruction
during periodontal diseases, periapical infections, maxillary
bone-sarcomas, and temporomandibular joint osteoarthritis
require a detailed analysis of a wide array of pathways. While
each disease in the oral and maxillofacial milieu has a distinct
etiological basis, recent work has demonstrated that several
mechanistic aspects could share common cellular and molecular
processes that are unique to the oral and maxillofacial structures.
In this work, we have reviewed the cutting-edge literature in
an attempt to identify the most current knowledge in the oral
osteoimmunology to provide new therapeutic approaches in
otherwise difficult to treat bone lesions. The characterization
of the different molecules involved in immune-mediated tissue
destruction has been identified to provide biomarkers that would
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be useful to comprehend the link between bone-destructive oral
diseases, such as periodontal disease and apical periodontitis,
with systemic diseases. Collectively, the work represents a
unique attempt to tackle common pathways of osteoimmunology
and osteoinflammation of the oral cavity, which presents a
highly unique environment colonized by the highest number of
bacterial species in the mammalian body and regulated by highly
functional biomechanical forces created by occlusion. Thus,
successful prevention and treatment of oral diseases require
recognition of this complexity to design specialized therapeutic
approaches and maintain the treatment outcomes.
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